What Is the Life Expectancy After Avastin for Ovarian Cancer?

There is no single life expectancy after Avastin. In the large trials, the midpoint survival with Avastin plus chemotherapy ran from about 16 months when the cancer had stopped responding to platinum chemotherapy to roughly 3 to 4 years when the drug was used at first diagnosis. Avastin (generic name bevacizumab) is added to chemotherapy to starve tumors of the new blood vessels they need to grow.¹ Its clearest effect is buying time before the cancer grows back, while a longer life overall is seen mostly in people whose cancer was more advanced or harder to operate on.²

Typical Survival Numbers With Avastin

Doctors usually quote survival as a median, the point where half of people lived longer and half shorter. They also quote progression-free survival, which is the time before the cancer grows again. That figure is usually shorter than total survival, so check which one a number refers to.

Here is how midpoint survival looked in the major trials:

First-diagnosis numbers look so much longer because most cancers still respond well to chemotherapy at that point. Recurrent cancer, especially the platinum-resistant kind, is harder to control.

A median is a single midpoint, and it hides the spread. Within the same trial group, some people lived only a few months and others lived many years. That makes a median a description of a group, not a prediction for any one woman. It also matters what the clock started from. Survival is usually counted from the start of treatment or enrollment in the trial, so check this before comparing two figures.

Trial results can also differ from everyday care. Trials accept only people who meet strict health criteria, so participants are often fitter than the typical person in a clinic, and they get scheduled scans and close monitoring. In ordinary hospital care outside trials, survival with Avastin has tended to be shorter.⁸ One platinum-resistant group in Canada had a midpoint of about 11 months.⁹ On the other hand, many of these trials ran years ago, and treatments available after regrowth have changed since, so today’s patients may do better than older figures suggest.

Does Avastin Help You Live Longer at First Diagnosis

In first-line trials, adding Avastin to chemotherapy delayed regrowth of the cancer.¹⁰ Across everyone in a large trial, though, it did not lengthen overall survival.¹¹ Another large trial found no overall survival gain either, even when Avastin was continued as maintenance, meaning Avastin alone after chemotherapy ends.¹²

A delay doesn’t always turn into a longer life. After the cancer regrows, people in both groups usually get further treatment, and that later treatment can narrow any gap Avastin opened up early. So a trial can show a clear delay in regrowth and still show no overall survival difference. The extra months aren’t worthless, either. They can mean months off chemotherapy with the cancer not growing, and for some people that is more time feeling relatively well.

The benefit does show up in higher-risk patients, where average survival rose from about 34.5 to 39.3 months.¹³ High-risk here means stage IV, or stage III where surgery left visible cancer behind or wasn’t possible.¹⁴ When surgery leaves visible cancer, more tumor remains to grow and spread, so a drug that slows tumor blood supply has more to act on. In lower-risk patients there was no survival difference.¹⁵ That is why some countries fund Avastin at diagnosis only for higher-risk patients.¹⁶

Avastin When Ovarian Cancer Comes Back

A platinum-sensitive recurrence means the cancer returned more than about 6 months after platinum chemotherapy. These cancers still respond to platinum drugs, which are among the most effective ovarian cancer chemotherapies, so those drugs form the core of treatment. Adding Avastin to chemotherapy here did not change midpoint survival in a large trial.¹⁷

Platinum-resistant means the cancer returned within about 6 months. Few effective options remain, which is why a drug that adds even a few months of control gets attention. Adding Avastin doubled the time before regrowth, from about 3.4 to 6.7 months.¹⁸ Tumors shrank in about 27% of people with Avastin versus 12% without.¹⁹ Because shrinkage happened in only about a quarter of people, most will not see their tumors shrink, and scans are how you find out. The gain in overall survival, however, was not statistically certain.²⁰ In real-world care, pairing it with weekly paclitaxel gave about 14 months versus 9 with other partners.²¹ Weekly paclitaxel did best in trials and real-world data, but the choice also depends on earlier side effects such as nerve damage, so it’s fair to ask why a given partner is recommended.

People who began Avastin at the first recurrence lived about 37 months after starting versus 19 at the third or fourth.²² That comes from records, so healthier people may simply have started earlier.

Who Benefits Most From Avastin

The surgery result matters. In a cancer registry, Avastin improved survival when surgery left cancer behind but not when all visible cancer was removed.²³ Leftover tumor is one of the strongest signs of how aggressive the disease is, and it is also where Avastin appears to help most. Surgeons describe the result as complete or incomplete removal of visible cancer, and that wording is worth asking about.

Among Avastin-treated patients, surgery before chemotherapy was linked to midpoint survival of about 52 months versus 27.5 when surgery came after.²⁴ That gap doesn’t show that timing caused the difference, since the groups were not chosen at random. Doctors often give chemotherapy first when the cancer is too widespread or the patient too frail for major surgery, so that group starts at a disadvantage.

Response to chemotherapy also seems to matter. CA-125 is a routine blood test of a tumor marker, and how fast it drops during the first cycles reflects how sensitive the cancer is to chemotherapy. High-risk patients whose CA-125 fell slowly gained about 6 months of survival with Avastin.²⁵ Those whose CA-125 fell quickly gained no clear benefit.²⁶ This came from a look back at one slice of a trial, so it suggests a pattern rather than proving one. A slow fall can reflect cancer that responds less to chemotherapy, which may be why extra treatment helps more there.

No test has yet been proven to predict who will benefit,²⁷ so your CA-125 trend should not by itself decide whether you take Avastin. You can still ask your team how your levels responded.

How Long Avastin Is Given and Can It Be Restarted

The standard first-line dose is 15 mg per kg every 3 weeks for 15 months.²⁸ In practice that means infusions every 3 weeks alongside chemotherapy, then Avastin alone as maintenance. Blood pressure and urine are checked before doses, and stopping early because of side effects is common and acceptable.

Extending to 30 months did not further delay regrowth.²⁹ That is why doctors stop at about 15 months, even for someone who feels well.

Some doctors restart Avastin when the cancer returns.³⁰ People retreated after a full response went about 20 months before regrowth versus 6 without it, but they did not live longer overall in that group.³¹ Whether to retreat depends on how well it worked before and on the side effects you had. Ask whether the aim is delay or survival.

Avastin Combined With Olaparib

Olaparib is a pill that can be taken up to 24 months alongside Avastin maintenance.³² Overall it delayed regrowth to about 22 months versus 17 with Avastin alone.³³ With HRD-positive tumors, meaning tumors that struggle to repair DNA, the delay was about 37 versus 18 months.³⁴

HRD stands for homologous recombination deficiency, a result showing that a tumor has trouble repairing certain DNA damage. Olaparib blocks another repair route, so cells that already struggle are left unable to survive. HRD-positive patients also lived longer on the combination.³⁵ In tumors that repair DNA normally, olaparib has little to exploit. HRD-negative patients did not benefit and did worse on overall survival in one analysis,³⁶ so testing before choosing matters.

Testing uses tumor tissue from surgery or a biopsy, and BRCA can also be checked in blood. The results guide the maintenance choice, so ask whether your tumor has been tested for HRD and BRCA.

Side Effects and Serious Risks

Most side effects are mild and manageable.³⁷ Avastin does raise the risk of high blood pressure, protein in urine, bleeding, slow wound healing, bowel tears, and blood clots,³⁸ and some side effects cause serious illness or death.³⁹ These problems arise because Avastin interferes with blood vessel growth, and the same process helps wounds heal and keeps vessel walls intact. High blood pressure is the most common issue and is usually handled with ordinary blood pressure medicine, which is why it is checked before doses.

Some symptoms need to be reported right away. Sudden severe belly pain could signal a bowel tear. Leg swelling or chest pain could signal a clot. A severe headache may mean very high blood pressure, and unusual bleeding needs prompt attention.

Risk differs by person. Recent surgery, past bowel problems, or radiation to the belly can raise the chance of a bowel tear, so tell your team about these before starting. Avastin is paused before and after surgery because of wound healing, so tell any surgeon or dentist you take it and ask how long to wait.

During chemotherapy, people on Avastin reported slightly lower quality of life, but during maintenance there was no difference.⁴⁰ Adding olaparib did not worsen quality of life.⁴¹

Cost and Biosimilars

In high-risk patients, one US estimate put the cost at about $168,000 per year of life gained.⁴² A Canadian analysis judged it cost-effective only for high-risk patients.⁴³ Health systems use such figures to decide who gets coverage. If cost is a worry, ask for a financial counselor. Manufacturer and charity assistance programs exist, and biosimilars may lower copays.

A biosimilar is a close copy of a biologic drug, made to match it in action and safety rather than being an identical chemical copy. Biosimilar versions have matched Avastin’s effect and safety in lung cancer trials.⁴⁴ That is a reasonable guide but not direct proof in ovarian cancer, so ask your oncologist whether one is appropriate for you, and ask your insurer which version is covered.